PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer.
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
/ genetics
Biomarkers, Tumor
/ genetics
Cell Line, Tumor
Female
Gene Expression Regulation, Neoplastic
Humans
Japan
Liver Neoplasms
/ genetics
Male
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
/ genetics
Prognosis
RNA, Messenger
/ genetics
Regression Analysis
Stomach Neoplasms
/ genetics
Survival Rate
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
29
07
2019
pubmed:
30
10
2019
medline:
3
2
2021
entrez:
30
10
2019
Statut:
ppublish
Résumé
Liver metastasis of gastric cancer (GC) is highly associated with poor prognosis. The development of sensitive biomarkers for detecting and predicting liver metastasis is required for better clinical outcome. In this study, we aimed to identify novel genes associated with liver metastasis of GC. Global expression profiling of 57,749 genes was performed using surgically resected gastric tissues from four patients with liver metastasis to identify candidate genes. The mRNA expression levels of the selected candidate gene were analyzed in the resected gastric tissues of 300 GC patients and correlated with clinicopathological parameters. Fourteen GC cell lines were subjected to mRNA expression and polymerase chain reaction (PCR) array analysis. Among 25 candidate genes identified by transcriptome analysis, preferentially expressed antigen of melanoma (PRAME) was selected for subsequent analyses. mRNA expression analysis of clinical samples revealed the aberrant expression of PRAME in GC tissues, and its high expression was significantly related to differentiated phenotype and vessel invasion, as well as liver metastasis. High PRAME expression was significantly associated with hepatic recurrence after curative surgery, and cumulative incidences of hepatic recurrence were significantly greater in patients with high PRAME expression compared with patients with low PRAME expression. In an in vitro analysis, overexpression was observed in all GC cell lines compared with a normal epithelial cell line. PCR array analysis revealed the coordinate expression of MMP9, OCLN, IL1RN, and MST1R. PRAME is related to the malignant potential of GC and could serve as a novel biomarker for the detection and prediction of liver metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
Liver metastasis of gastric cancer (GC) is highly associated with poor prognosis. The development of sensitive biomarkers for detecting and predicting liver metastasis is required for better clinical outcome.
OBJECTIVE
OBJECTIVE
In this study, we aimed to identify novel genes associated with liver metastasis of GC.
METHODS
METHODS
Global expression profiling of 57,749 genes was performed using surgically resected gastric tissues from four patients with liver metastasis to identify candidate genes. The mRNA expression levels of the selected candidate gene were analyzed in the resected gastric tissues of 300 GC patients and correlated with clinicopathological parameters. Fourteen GC cell lines were subjected to mRNA expression and polymerase chain reaction (PCR) array analysis.
RESULTS
RESULTS
Among 25 candidate genes identified by transcriptome analysis, preferentially expressed antigen of melanoma (PRAME) was selected for subsequent analyses. mRNA expression analysis of clinical samples revealed the aberrant expression of PRAME in GC tissues, and its high expression was significantly related to differentiated phenotype and vessel invasion, as well as liver metastasis. High PRAME expression was significantly associated with hepatic recurrence after curative surgery, and cumulative incidences of hepatic recurrence were significantly greater in patients with high PRAME expression compared with patients with low PRAME expression. In an in vitro analysis, overexpression was observed in all GC cell lines compared with a normal epithelial cell line. PCR array analysis revealed the coordinate expression of MMP9, OCLN, IL1RN, and MST1R.
CONCLUSIONS
CONCLUSIONS
PRAME is related to the malignant potential of GC and could serve as a novel biomarker for the detection and prediction of liver metastasis.
Identifiants
pubmed: 31659640
doi: 10.1245/s10434-019-07985-6
pii: 10.1245/s10434-019-07985-6
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
PRAME protein, human
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2071-2080Références
Bray F, Ferlay J, Soerjomtaram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
doi: 10.3322/caac.21492
Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006;12:3237–42.
doi: 10.3748/wjg.v12.i20.3237
Sakamoto Y, Sano T, Shimada K, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 2007;95:534–9.
doi: 10.1002/jso.20739
Tiberio GA, Coniglio A, Marchet A, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35:486–91.
doi: 10.1016/j.ejso.2008.12.017
Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v50–4.
doi: 10.1093/annonc/mdq164
Umeda S, Kanda M, Miwa T, et al. Expression of sushi domain containing two reflects the malignant potential of gastric cancer. Cancer Med. 2018;7:5194–204.
doi: 10.1002/cam4.1793
Sawaki K, Kanda M, Miwa T, et al. Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer. Ann Surg Oncol. 2018;25:2083–90.
doi: 10.1245/s10434-018-6480-z
Kanda M, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667–79.
doi: 10.18632/oncotarget.7269
Liu JY, Peng CW, Yang XJ, Huang CQ, Li Y. The prognosis role of AJCC/UICC 8(th) edition staging system in gastric cancer, a retrospective analysis. Am J Transl Res. 2018;10:292–303.
pubmed: 29423014
pmcid: 5801367
Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.
doi: 10.1016/j.surg.2015.05.017
Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol. 2014;20:13718–27.
doi: 10.3748/wjg.v20.i38.13718
Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–49333.
doi: 10.18632/oncotarget.10337
Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res. 2006;66:10639–42.
doi: 10.1158/0008-5472.CAN-06-2522
Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer. 2010; 9:226.
doi: 10.1186/1476-4598-9-226
Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199–208.
doi: 10.1016/S1074-7613(00)80426-4
Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer. 2008;99:398–403.
doi: 10.1038/sj.bjc.6604494
Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr, Zago MA. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck. 2006;28:614–9.
doi: 10.1002/hed.20380
Thongprasert S, Yang PC, Lee JS, et al. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients. Lung Cancer. 2016;101:137–44.
doi: 10.1016/j.lungcan.2016.09.006
Ercolak V, Paydas S, Bagir E, et al. PRAME Expression and Its Clinical Relevance in Hodgkin’s Lymphoma. Acta Haematol. 2015;134:199–207.
doi: 10.1159/000381533
Tan P, Zou C, Yong B, et al. Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Commun. 2012;419:801–8.
doi: 10.1016/j.bbrc.2012.02.110
Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J Cell Physiol. 2011;226:322–30.
doi: 10.1002/jcp.22417
Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–93.
doi: 10.1038/35106036
Al-Khadairi G, Naik A, Thomas R, Al-Sulaiti B, Rizly S, Decock J. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med. 2019;17:9.
doi: 10.1186/s12967-018-1757-3
Chang H, Liu Y, Xue M, et al. Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition. Nucleic Acids Res. 2016;44:2514–27.
doi: 10.1093/nar/gkw126
Oki E, Tokunaga S, Emi Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968–76.
doi: 10.1007/s10120-015-0530-z
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.
doi: 10.1200/JCO.2011.36.5908
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.
doi: 10.1016/S0140-6736(11)61873-4
Kanda M, Murotani K, Tanaka H, et al. Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget. 2018;9:18775–85.
pubmed: 29721160
pmcid: 5922354
Tanaka H, Kanda M, Shimizu D, et al. FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer. Ann Surg Oncol. 2017;24:3438–45.
doi: 10.1245/s10434-016-5636-y